Creative Planning
ENTA icon

Creative Planning’s Enanta Pharmaceuticals ENTA Stock Holding History

Creative Planning’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,245
Closed -$155K – 4341
2026
Q1 		$155K Buy
+12,245
New +$164K ﹤0.01% 3805
2016
Q1 		– Sell
-37
Closed -$1K – 4370
2015
Q4 		$1K Hold
37
– – ﹤0.01% 4196
2015
Q3 		$1K Buy
+37
New +$1.59K ﹤0.01% 4083
2015
Q1 		– Sell
-374
Closed -$19K – 4260
2014
Q4 		$19K Sell
374
-481
-56% -$21.5K ﹤0.01% 2686
2014
Q3 		$34K Buy
+855
New +$34.1K ﹤0.01% 2175
2014
Q2 		– Sell
-706
Closed -$28K – 3816
2014
Q1 		$28K Sell
706
-912
-56% -$33.1K ﹤0.01% 2173
2013
Q4 		$44K Buy
1,618
+1,076
+199% +$26.1K ﹤0.01% 1685
2013
Q3 		$12K Buy
+542
New +$10.4K ﹤0.01% 2351

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Creative Planning's ENTA Position: Q2 2026 in Review

Creative Planning sold out of Enanta Pharmaceuticals (ENTA) in Q2 2026, closing a stake of 12,245 shares — an estimated $155K sold.

Creative Planning first reported a position in ENTA in Q3 2013 and held it in 8 quarters. The position peaked at $155K in Q1 2026. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Creative Planning reported no remaining Enanta Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Creative Planning sold 12,245 Enanta Pharmaceuticals shares in Q2 2026, an estimated $155K.
  • Creative Planning first reported a position in Enanta Pharmaceuticals in Q3 2013 and held it in 8 quarters.
  • Creative Planning's Enanta Pharmaceuticals position peaked at $155K in Q1 2026.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.